These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27173004)

  • 1. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
    Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
    J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
    Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
    ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
    Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into histone lysine demethylation.
    Hou H; Yu H
    Curr Opin Struct Biol; 2010 Dec; 20(6):739-48. PubMed ID: 20970991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.
    Nalawansha DA; Pflum MK
    ACS Chem Biol; 2017 Jan; 12(1):254-264. PubMed ID: 27977115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
    Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Histone Methylation in Cancer.
    McCabe MT; Mohammad HP; Barbash O; Kruger RG
    Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and function of histone H3 lysine 9 methyltransferases and demethylases.
    Krishnan S; Horowitz S; Trievel RC
    Chembiochem; 2011 Jan; 12(2):254-63. PubMed ID: 21243713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.
    Lillico R; Sobral MG; Stesco N; Lakowski TM
    J Proteomics; 2016 Feb; 133():125-133. PubMed ID: 26721445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Lysine Demethylase Inhibitors.
    Jambhekar A; Anastas JN; Shi Y
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 28049654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
    Niwa H; Umehara T
    Epigenetics; 2017 May; 12(5):340-352. PubMed ID: 28277979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.